Dynavax Doses First Participants in Phase 1 Trial of Medicago’s Plant-Derived COVID-19 Vaccine

Dynavax Technologies Corporation (Emeryville, CA, USA) has dosed the first participants in the Phase 1 clinical trial evaluating Medicago’s (Quebec City, Canada) plant-derived vaccine candidate adjuvanted with CpG 1018 to prevent COVID-19.

The companies have entered into a collaboration for evaluating the combination of Medicago’s Coronavirus Virus-Like Particle (CoVLP) with Dynavax’s CpG 1018, the adjuvant contained in Dynavax’s US FDA-approved adult hepatitis B vaccine. Adding CpG 1018 is intended to enhance the immune response of Medicago’s COVID-19 vaccine which may reduce the amount of antigen required per dose, providing more doses to help protect a greater number of people.


The study is a Phase 1 randomized, partially-blinded, prime-boost, staggered dose-escalation study intended to assess the safety, tolerability, and immunogenicity of the Coronavirus-Like Particle COVID-19 Vaccine at three dose levels (3.75 µg, 7.5 µg, and 15 µg VLP) unadjuvanted or adjuvanted with either CpG 1018, or another company’s adjuvant, in approximately 180 healthy subjects 18 to 55 years of age, who have been tested for the absence of SARS-CoV-2 antibodies. Preliminary safety and immunogenicity results are expected in October 2020. Medicago is also planning a Phase 2/3 trial to be initiated this October.

Medicago’s plant-based production platform will be used to manufacture the COVID-19 vaccine antigen. This platform uses plants as mini-factories which create proteins that self-assemble into the virus-like particles that are used in the CoVLP vaccine candidate. Combining Medicago’s technology with Dynavax’s CpG 1018 adjuvant, the companies expect to be able to deliver up to 100 million doses by the end of 2021. By the end of 2023, Medicago expects to complete the construction of a large-scale manufacturing facility in Quebec City, Canada that Medicago anticipates will have the capacity to produce up to one billion vaccine doses annually.

“We are committed to supporting the development of an adjuvanted vaccine to prevent COVID-19,” said Ryan Spencer, Chief Executive Officer of Dynavax. “CpG 1018’s ability to enhance the immune response, as successfully demonstrated in HEPLISAV-B, is expected to reduce the dose of antigen needed, helping ensure broader availability to patients. Additionally, the unique mechanism of action of CpG 1018 may provide important enhancements including increased protection in populations traditionally less responsive to vaccination such as older adults who are at greatest risk for severe disease from COVID-19.”

Related Links:
Dynavax Technologies Corporation
Medicago